



# MOREPEN



**Date:** 31/08/2020

To,

**National Stock Exchange of India Ltd.**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051  
Tel No: (022) 26598100 - 8114  
Fax No: (022) 26598120  
**Symbol: MOREPENLAB**

**BSE Limited**

Floor 25, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400 001  
Phones: 91-22-22721233/4  
Fax: 91-22-2272 3121  
**Scrip Code: 500288**

**Subject: Investors Presentation (Q1' FY21) August, 2020**

Dear Sir,

Please find enclosed the **Investors Presentation (Q1' FY21) August, 2020**, based on the financial performance of the Company for the quarter ended 30<sup>th</sup> June, 2020.

Kindly acknowledge the receipt and take it on your record.

Thanking you.

Yours faithfully,

**For Morepen Laboratories Limited**



**(Vipul Kumar Srivastava)**  
**Company Secretary**

**Encl.: As Above**

**Morepen Laboratories Limited**

**Corp. Off.:** 4th Floor, Antriksh Bhawan, 22 K.G. Marg, New Delhi- 110 001, INDIA  
Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: www.morepen.com  
CIN NO. L24231 HP1984PLC006028

**Plant & Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205  
Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com



I CHOOSE  
**JOY**



**MOREPEN**  
*The Joy Of Growing Together*

INVESTORS PRESENTATION (Q1'FY21) AUGUST 2020

**Disclaimer:**

*This presentation has been prepared by Morepen Laboratories Limited ("Company") solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking statements, including discussions of our future plans, strategy, research and deployment activities and products in pipeline. Such forward looking statements reflect current views of the Company or its subsidiaries regarding future events, and involve known or unknown risks, uncertainties and other factors that may cause actual results to be different from any future results expressed or implied by such statements.*

*This presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this presentation. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. This presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this presentation is expressly excluded. The Company is providing the information in this presentation as of date and does not undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise.*

*The contents of this presentation are confidential and should not be distributed, published or reproduced, in whole or part, or disclosed by recipients, either directly or indirectly, to any other person. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence, investigations, etc. may be conducted at the end of the recipient.*

*This presentation does not constitute or form part of and should not be construed, either directly or indirectly, as any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company by any person in any jurisdiction. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India.*

# Highlights of Q1'FY21



## Consolidated Performance

₹ crores

- *Net Revenue in Q1'FY21 up by 27% at Rs. 258.97 crore from Rs. 203.26 crore in Q1'FY20.*
- *Net Profit before tax has jumped by 155% at Rs. 19.56 crore against Rs.7.68 crores in Q1'FY20.*
- *EBDITA has moved up at Rs. 27.90 crore, up 42% from Rs. 19.61 in Q1'FY20.*
- *Cash Profits shot up by 44% at Rs. 27.61 crore against Rs.19.18 crores last year same quarter .*
- *API sales marked a record growth of 44% in the Q1'FY21, Export up 47%, Domestic up 36%*
- *BP Monitors sales jump up by 57% while total diagnostics sales grew by 16%*
- *OTC Business sales recorded a remarkable growth of 53% with large contribution from Covid range*
- *Net profit after tax grew by 153% at Rs. 19.37 crores as compared to Rs. 7.66 crores for Q1'FY20.*
- *Board approves API expansion plan of Rs.178 crores*

# Q1 Segment wise growth:



- **Overall business** for the quarter (Q1'FY21) has registered growth of **27%** as compared to Q1'FY20 despite market disruptions due to complete lockdown in major markets.
- **API Business** has registered a growth of **44%** for the year Q1'FY'21 and has contributed 64% to the consolidated sales revenue and **68%** to the standalone revenue against 60% of consolidated sales revenues last year same quarter.
- **Home Diagnostic Devices** business constituting **18%** to the topline has shown decent growth of **16%** in Q1'FY'21 as compared to Q1'FY20 with introduction of new products.
- **OTC Business** has been able to scale excellent growth of **53%** during the current quarter thanks to launch of range of Covid essentials.
- **Finished dosage** business had faced difficulty reaching the market due to Covid lockdowns and overall business has registered a drop of 31% against the Q1'FY'20 revenues.



Segments	Q1'FY21	Q1'FY20	Y-o-Y Growth
APIs	162.06	112.42	44%
Diagnostics	46.56	40.03	16%
OTC	21.69	14.16	53%
Formulations	23.04	33.29	(31%)

# API: Taking the lead

- **API business** increases its lion's share in company's revenues to **64%** and has **grown by 44%** on Q-o-Q basis despite lockdown in various markets in India and abroad.
- In the **Export** market business grew by more than **47%** and in the **Domestic** market also API business marked a growth of **36%**.
- All existing products comprising of Loratadine, Atorvastatin, Fexofenadine and Rosuvastatin scaled new heights during the current quarter - Q1'FY21





Main Products	Q1'FY21	Q1'FY20	Growth
APIs	<b>142.88</b>	100.12	<b>43%</b>
Intermediates	<b>11.67</b>	6.11	<b>91%</b>
New Molecules	<b>7.51</b>	6.19	<b>21%</b>

# Regulated Markets Exports Soared

₹ crores

- **Asia pacific Export business** has got **57%** share in the export business for the year FY'21 and a good growth of **45%** as compared to FY'20.
- **Europe market** has shown spectacular increase of **127%**, **USA business** has down by **20%** this quarter due to lockdowns.
- **Other semi-regulated markets** have given an excellent growth of **38%**
- **Board had approved API expansion plan of Rs.178 crores**



Region	Q1'FY21	Q1'FY20	Growth
APAC	66.43	45.96	45%
Europe	32.43	14.26	127%
USA	11.53	14.41	(20%)
Others	6.73	4.87	38%

## Mega Expansion plan- Rs.178 crores

- Company's Board has approved a mega expansion plan involving an outlay of Rs. 178 crore for existing products and the strong pipeline of APIs under development.
- The plan has already been approved by Himachal State Government under single window clearance scheme and environmental clearance by State Level Approval Committee is awaited.
- This expansion would add 2000 MT p.a. manufacturing capacity in addition to 3000 MT p.a. capacity already installed and will facilitate production of over 40 new and existing bulk drugs.
- The expanded capacity is likely to commence commercial production over the next 2-3 years in a phased manner and would generate additional employment for about 700 people.
- The company proposes to fund the expansion by a combination of internal accruals and outside funding as may be proposed by the Board.
- Expansion plan of API manufacturing facility is well in sync with present global trend where all major companies are shifting their outsourcing from China.
- Indian API industry is rightly placed to become the global outsourcing hub for foreign pharmaceutical giants, with best international quality standards supported by complete documentation and FDA approvals in place.
- Govt. of India has also come forward in a very aggressive manner to support this mission and make India self-reliant in APIs.





Baddi API Plant: Arial View



## Devices Business – Performance

- **Home Devices portfolio** has achieved a good growth of 16% during the quarter compared to corresponding period last year. In order to fight the Covid-19 battle, company launched Non-Contact Infrared Thermometers in the month of April 2020.
- **Thermometer** sales for the quarter had jump of around twenty times (20x) as compared to Q1'FY20 due launch of Non-contact thermometers.
- **Blood pressure monitors sales** have registered a incredible growth of 57% during the current quarter against Q1'FY20 revenues.
- Company also started manufacturing Oximeters in India in the Q1'FY21 due to increased demand.
- With 30 million Gluco Monitoring strips being sold during the quarter, the number of strips being used by the consumers has crossed 450 million.






# New <sup>NEW</sup> Launches: Oxygen Concentrator for Covid Care

Dr. Morepen®  
**OXYGEN  
CONCENTRATOR**  
MODEL: OC-01

0-5 LPM FLOW RATE

93% ± 3% O<sub>2</sub> Concentration



20-60 kPa OUTPUT PRESSURE



Dr. Morepen®

# OTC Business Shines all the way

- OTC category in total has been able to score a stunning growth of **53%** during the quarter on the strength of 50% growth in grooming business and introduction of Covid range of products.
- The Company launched a wide range of, **hand sanitizers, hand rubs, hand wash, anti-bacterial spray, anti-bacterial soap, disinfectant solutions, face masks, gloves, Vitamin - C gummies for kids, Multivitamins, Chyawanprash and Curcumin tablets** to fight Covid-19 in the marketplace.
- **Covid Range** contributed more than **61%** to the top line of the OTC business during the quarter.



Segments	Q1'FY21	Q1'FY20	Q-o-Q Growth
Lead Brands	2.89	7.03	(59%)
Covid Range	13.26	-	100%
Other Brands	5.54	7.14	(22%)



**Dr. Morepen<sup>3</sup>**

### Covid Essentials

The image displays a variety of products from the 'Covid Essentials' line. It includes several bottles of 'Protect' brand hand sanitizer and disinfectant in different scents like 'ROSE' and 'EUCALYPTUS'. There are also larger jugs of disinfectant, a box of 'Protect' nitrile gloves, several surgical masks, and various supplement bottles including 'Burnol Active Solution', 'Chyawanprash', and 'C-Candy Vitamin-C Gummy'. A digital thermometer is also visible on the right side.

**NEW**

### Your *Beauty* Solution For *Skin* Ageing




**STRONG 7gm MARINE COLLAGEN TO IMPROVE**

- ✓ **Skin Firmness**
- ✓ **Hydration**
- ✓ **Glow**
- ✓ **Reduce Fine Lines & Pores**

APPROVED  
BY  
DR. MOREPEN

# Profit after tax jumps 153%

- **EBIDTA** has scaled up from Rs. 19.61 crores to Rs. 27.90 crores, a significant jump of **42%** during the year Q1'FY21 on account of increased topline and controlled expenses.
- **Cash Profits** during the year Q1'FY21 has also taken a leap of **44 %** as compared to last year same quarter.
- **Net profit before tax (PBT)** has risen to Rs.19.56 crores as against Rs. 7.68 crores in the year Q1'FY21, a major jump of **155%** against Q1'FY20.
- **Net profit after tax (PAT)** for Q1'FY21 is Rs.19.37 crores as compared to Rs. 7.66 crores in Q1'FY20 registering a high jump of **153%**.
- Accordingly, **Earning per share (EPS)** for the **Q1** of the company has also moved from Rs. 0.17 to Rs. 0.43 registering a jump of **153%**



# Q1'FY21 Performance - Standalone

₹ crores

<b>Particulars</b>	<b>Q1'FY21</b>	<b>Q1'FY20</b>	<b>Q-o-Q Growth</b>
Net Revenue	<b>244.58</b>	189.75	28.89%
Expenditure	<b>217.98</b>	170.02	28.20%
<b>EBIDTA</b>	<b>26.60</b>	19.73	34.85%
Interest	<b>0.28</b>	0.42	(32.33%)
Cash Surplus	<b>26.32</b>	19.31	36.32%
Dep. & Amortization	<b>7.47</b>	10.90	(31.45%)
<b>Profit before Tax</b>	<b>18.85</b>	8.41	124.16%
Tax	-	-	-
<b>Net Profit after Tax</b>	<b>18.85</b>	8.41	124.16%

# Q1'FY21 Performance - Consolidated

₹ crores

<b>Particulars</b>	<b>Q1'FY21</b>	<b>Q1'FY20</b>	<b>Q-o-Q Growth</b>
Net Revenue	<b>258.97</b>	203.26	27.40%
Expenditure	<b>231.07</b>	183.65	25.81%
<b>EBIDTA</b>	<b>27.90</b>	19.61	(42.26%)
Interest	<b>0.29</b>	0.43	(33.27%)
Cash Surplus	<b>27.61</b>	19.18	43.94%
Dep. & Amortization	<b>8.05</b>	11.50	(29.95%)
<b>Profit before Tax</b>	<b>19.56</b>	7.68	154.61%
Tax	<b>0.19</b>	0.02	-
<b>Net Profit after Tax</b>	<b>19.37</b>	7.66	152.73%



*Thank You*

I CHOOSE  
**JOY**

